- Familial Cancer testing
- Hereditary Cancer testing
- Inherited Cancer testing
- Multiple Endocrine Neoplasia
CDC73, MAX, MEN1, NF1, PRKAR1A, PTEN, RET, SDHB, SDHC, SDHD, TMEM127, TP53, and VHL.
A hereditary cancer clinical questionnaire should be submitted with all specimens. Contact CMBP genetic services at 800-345-4363 to coordinate testing.
Expected Turnaround Time
23 - 28 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Whole blood or saliva collected in an Oragene Dx collection kit
10 mL whole blood, 2 mL saliva
7 mL whole blood, 0.5 mL saliva
Lavender-top (EDTA) tube or yellow-top (ACD) tube or Oragene Dx 500 saliva collection kit
Blood is collected by routine phlebotomy. Saliva is collected by spitting into the provided container until it reaches the fill line.
Causes for Rejection
Frozen specimen; leaking tube; clotted specimen; grossly or hemolyzed specimen; quantity not sufficient for analysis; incorrect anticoagulant; saliva collection in an incorrect container. Do not eat, drink, smoke, or chew gum 30 minutes prior to saliva sample collection. See Oragene Dx 500 saliva kit for detailed instructions.
This assay is intended for patients with a family history consistent with an inherited cancer syndrome.
Sequencing cannot detect variants in regions not covered by this analysis, including noncoding or deep intronic variants and may not reliably detect changes in repetitive elements, such as microsatellite repeats. Sequencing may not detect mosaic variants, inversions, or other genomic rearrangements such as transposable element insertions. Sequence analysis may also be affected by allele drop-out due to the presence of a rare variant under a primer site or homopolymeric regions. The method does not allow any conclusion as to whether two heterozygous variants are presenton the same or on different chromosome copies.
Copy number variations are assessed by microarray or multipleligation-probe amplification assay (MLPA) to detect gross deletions and duplications. Copy number analyses are designed to detect single exon, multi-exon, and full gene deletions orduplications. These analyses may not detect certain genomic rearrangements, such as translocations (balanced or unbalanced), inversions, or some partial exon rearrangements. This assay cannot determine exact breakpoints of deletions or duplications detected.
The presence of pseudogenes can interfere with the ability todetect variants in certain genes. For example, deletion/duplication analysis of PMS2 exons 11-15, among others, is complicated by the highly homologous PMS2CL pseudogene. Deletions/duplications in PMS2CL have not been associated with Lynch syndrome; however, this assay may not be able to determine if a deletion/duplication affects PMS2 or PMS2CL.
Each gene sequence is interpreted independently of all other gene sequences; however, variants in different genes may interact to cause or modify a typically monogenic disease phenotype.
In addition, the presence of an inherited cancer syndrome due to a different genetic cause cannot be ruled out. Any interpretation given should be clinically correlated with available information about presentation and the patient's relevant family history.
This test is not intended to detect somatic variants. Bone marrow transplantation may affect the outcome of these results. Please contact Labcorp at 1-800-345-GENE to discuss testing options.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
The coding region and flanking splice sites are analyzed by NGS (+/-10bp) and deletion/duplication analysis. Exon-level deletions/duplications are assessed by aCGH or by MLPA. Analysis is expanded to include promoter sequence variants for PTEN (c.-1300 to c.-750). Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|481374||VistaSeq Endocrine Cancer||73977-1||481375||Specimen Type||31208-2|
|481374||VistaSeq Endocrine Cancer||73977-1||481376||Preauthorization||N/A|
|481374||VistaSeq Endocrine Cancer||73977-1||481377||Result Summary||51968-6|
|481374||VistaSeq Endocrine Cancer||73977-1||481378||Result and Interpretation||69548-6|
|481374||VistaSeq Endocrine Cancer||73977-1||481379||Recommendations||47042-7|
|481374||VistaSeq Endocrine Cancer||73977-1||481380||Additional Information||77202-0|
|481374||VistaSeq Endocrine Cancer||73977-1||481381||Methodology and Limitations||49549-9|
|481374||VistaSeq Endocrine Cancer||73977-1||481382||References||75608-0|
|481374||VistaSeq Endocrine Cancer||73977-1||481383||Director Review||72486-4|
|481374||VistaSeq Endocrine Cancer||73977-1||481384||51969-4|